Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1504-1510

  Massard, Christophe ^a   Tran Ba Loc, Pierre ^a   Haddad, Vincent ^a   Pignon, Jean Pierre ^a   Girard, Philippe ^b   Monnet, Isabelle ^c   Trédaniel, Jean ^d   Besse, Benjamin ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c Centre Inter Communal de Crétail   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Adjuvant chemotherapy; Guidelines; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CENTRAL VENOUS INFECTION; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FRANCE; HUMAN; INFECTION; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; POSTOPERATIVE COMPLICATION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT INDICATION; VOMITING;

EID: 74249119931     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181bbf1c9     Document Type: Article

References (30)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-485.
4. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
5. Mamounas EP. Can we approach zero relapse in breast cancer? Oncologist 2005;10(Suppl 2):9-17.
6. Bleiberg H. Adjuvant treatment of colon cancer. Curr Opin Oncol 2005;17:381-385.
7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
8. Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 2005;128:2933-2943.
9. Rosell R, Felip E, Maestre J, et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 2001;34(Suppl 3):S63-S74.
10. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350: 351-360. (Pubitemid 38101630)
11. Winton T, Livingston R, Johnson D, et al.; National Cancer Institute of Canada Clinical Trials Group, National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
12. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
13. Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
14. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
15. Alam N, Darling G, Evans WK, Mackay JA, Shepherd FA; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence- Based Care. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 2006;58: 146-155.
16. Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007;2:39-43.
17. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006;106:2452-2458.
18. Pepe C, Hasan B, Winton TL, et al. National Cancer Institute of Canada and Intergroup Study JBR. 10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol 2007;25:1553-1561.
19. Früh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected nonsmall- cell lung cancer. J Clin Oncol 2008;26:3573-3581.
20. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with nonsmall cell lung cancer: a review of the evidence. Chest 2005;128:947-957.
21. Asmis TR, Ding K, Whitehead M, et al. Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized national cancer institute of Canada Clinical Trials Group (NCIC CTG) trials. ASCO Meet Abstr 2006;24: 7117.
22. Firat S, Byhardt RW, Gore E. Comorbidity and karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phy 2002;54:357-364.
23. Ravdin PM. How can prognostic and predictive factors in breast cancer be used in a practical way today? Recent Results Cancer Res 1998;152: 86-93.
24. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature. Lung Cancer 2005;47:385-394.
25. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
26. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Freeman J, Goodwin JS. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 2006;98:382-388.
27. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006. (Pubitemid 46224006)
28. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
29. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-2756.
30. Olivotto A, Coldman AJ, Hislop TG, et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997;15:216-222.